+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antibiotics Market Report by Action Mechanism, Drug Class, Spectrum of Activity, Route of Administration, End User, and Region 2024-2032

  • PDF Icon

    Report

  • 137 Pages
  • August 2024
  • Region: Global
  • IMARC Group
  • ID: 5901321
The global antibiotics market size reached US$ 51.4 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 70.7 Billion by 2032, exhibiting a growth rate (CAGR) of 3.61% during 2023-2032. The growing prevalence of pneumonia, tuberculosis, and other infectious diseases among individuals, rising occurrence of antimicrobial resistance (AMR), and technological advancements in biotechnology and drug discovery techniques are some of the major factors propelling the market.

Antibiotics are a class of medications that are used to treat bacterial infections. They are widely available in various forms, such as pills, capsules, injections, creams, and ointments. They either kill bacteria or inhibit their growth to effectively eliminate infections. They target specific mechanisms or structures within bacterial cells and interfering with their vital functions and preventing their reproduction. Besides this, they assist in enhancing the immune system of individuals. As a result, antibiotics are utilized to treat various diseases, such as urinary tract infections (UTI), respiratory tract infections, skin infections, and certain sexually transmitted diseases among individuals.

At present, the increasing prevalence of numerous chronic diseases among the masses around the world is contributing to the growth of the market. Additionally, the wide availability of antibiotics through online and offline stores across the globe is strengthening the growth of the market. Apart from this, the growing demand for topical antibiotics, as they minimize the risk of surgical site infections among individuals, is positively influencing the market.

Moreover, the increasing employment of antibiotics in livestock farming to safeguard animal health and welfare and support food safety is bolstering the growth of the market. In line with this, the rising demand for antibiotics among the geriatric population is supporting the growth of the market. Furthermore, the increasing consumer awareness about preventive healthcare measures is impelling the growth of the market.

Antibiotics Market Trends/Drivers:

Rising prevalence of infectious diseases

There is a rise in the prevalence of infectious diseases, such as pneumonia, tuberculosis, urinary tract infections (UTI), gastrointestinal infections, and sepsis, among the masses across the globe. People are increasingly suffering from these diseases due to inadequate sanitation, which contributes to the spread of bacterial infections. In addition, the emergence of drug-resistant bacteria is increasing the demand for antibiotics.

There is a rise in the demand for effective antibiotics that assist in treating these infections. Antibiotics are specifically designed to target and eliminate bacterial infections. They effectively kill bacteria in the body and promote healing among individuals. Furthermore, antibiotics are used under the guidance of healthcare professionals to optimize patient outcomes.

Increasing occurrence of antimicrobial resistance (AMR)

There is a rise in the occurrence of antimicrobial resistance (AMR) across the globe, which is driving the antibiotics market. AMR occurs when bacteria, viruses, parasites, or fungi evolve and become resistant to the drugs used to treat them. It reduces the effectiveness of antibiotics and causes longer and more severe infections, increased healthcare costs, and high mortality rates among individuals.

Overuse and misuse of antibiotics are contributing to the development of drug-resistant bacteria, which makes traditional antibiotics less effective. In addition, multidrug-resistant strains, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Carbapenem-resistant Enterobacteriaceae (CRE), are more prevalent. This necessitates the development of new antibiotics or alternative treatments to combat these resistant strains.

Technological advancements in antibiotics

Innovations in biotechnology, molecular biology, and drug discovery techniques assist in improving the efficiency and effectiveness of antibiotic development. Genomics and high-throughput screening allow the identification of potential drug targets and the screening of large compound libraries. Moreover, computer-aided drug design enables the prediction of drug efficacy and optimizes antibiotic candidates. These technological advancements streamline the antibiotic discovery process and reduce the time and costs associated with traditional methods.

Additionally, advancements in diagnostic techniques, such as rapid pathogen identification and susceptibility testing, assist in appropriate antibiotic selection and prescribing that provides enhanced patient outcomes. Furthermore, technological advancements aid in the development of new and more potent antibiotics to address infectious diseases and antimicrobial resistance.

Antibiotics Industry Segmentation:

The publisher provides an analysis of the key trends in each segment of the global antibiotics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on action mechanism, drug class, spectrum of activity, route of administration and end user.

Breakup by Action Mechanism:

  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • Mycolic Acid Inhibitors
  • Others

Cell wall synthesis inhibitors represent the largest market segment


Cell wall synthesis is a class of antibiotics that target the bacterial cell wall. These antibiotics interfere with the process of cell wall synthesis, which causes cell wall damage and eventual bacterial death. In addition, penicillin, cephalosporins, and carbapenems are some of the cell wall synthesis inhibitors. They work by inhibiting enzymes called penicillin-binding proteins (PBPs) that are involved in the cross-linking of peptidoglycan chains. Moreover, cell wall synthesis inhibitors are particularly effective against gram-positive bacteria due to their thicker peptidoglycan layer, which provides a greater target for disruption.

Breakup by Drug Class:

  • Cephalosporin
  • Penicillin
  • Fluoroquinolone
  • Macrolide
  • Carbapenem
  • Aminoglycoside
  • Others

Penicillin accounts for the majority of the market share


Penicillin is a widely used class of antibiotics that belongs to the beta-lactam drug class. It works by inhibiting the synthesis of bacterial cell walls that causes cell wall damage and bacterial death. It is considered an essential medicine and is widely available as generic drugs. Apart from this, it is widely used in various healthcare settings, such as hospitals, clinics, and outpatient settings. In addition, the rising utilization of penicillin, as it is effective against various bacterial infections, is contributing to the growth of the market.

Breakup by Spectrum of Activity:

  • Broad-Spectrum Antibiotics
  • Narrow-Spectrum Antibiotics

Broad-spectrum antibiotics hold the biggest market share


Broad-spectrum antibiotics are a class of antibiotics that exhibit activity against a wide range of bacteria, such as gram-positive and gram-negative bacteria. In line with this, the rising adoption of broader spectrum antibiotics, as they are effective against a broader range of microorganisms compared to narrow-spectrum antibiotics, is bolstering the growth of the market. Apart from this, broad-spectrum antibiotics assist in treating infections when the causative bacteria are unknown or when the infection involves multiple bacterial species. The appropriate use of broad-spectrum antibiotics minimizes the risks of infections in the body.

Breakup by Route of Administration:

  • Oral
  • Parenteral
  • Topical
  • Others

Parenteral dominates the market segment


Parenteral antibiotics are administered via routes other than the digestive tract, such as intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes. These routes allow for direct delivery of the medication into the bloodstream or deep tissues, bypassing the gastrointestinal system. In addition, parenteral antibiotics provide rapid and predictable drug absorption and immediate therapeutic effect. They are also suitable for patients with compromised gastrointestinal function. Apart from this, it allows for accurate dosing and is particularly beneficial in cases where high drug concentrations are needed or when oral administration is not possible.

Breakup by End User:

  • Hospitals
  • Specialty Clinics
  • Others

Hospitals accounted for the largest market share


Antibiotics are widely consumed in hospitals due to the increased number of patients staying in this healthcare setting. Antibiotics are administered to patients admitted with severe infections. They are also administered before surgical procedures to reduce the risk of bacterial contamination. In line with this, the rising utilization of antibiotics among individual post-surgical prophylaxis is contributing to the growth of the market. Apart from this, the increasing consumption of antibiotics due to the rising risk of multidrug-resistant infections in hospitals is supporting the growth of the market.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Asia Pacific exhibits a clear dominance, accounting for the largest antibiotics market share


Asia Pacific held the biggest market share due to the improved healthcare infrastructure. In line with this, the growing prevalence of bacterial infections to poor sanitation is contributing to the growth of the market in the Asia Pacific region. Apart from this, the increasing demand for advanced antibiotics that can effectively combat multidrug-resistant bacteria is supporting the growth of the market. Furthermore, the presence of a large number of generic drug manufacturers is propelling the growth of the market in the region.

Competitive Landscape:

Key players in the industry are investing in research and development (R&D) activities to discover and develop new antibiotics and focusing on antibiotic resistance, expanding the spectrum of activity, and improving the efficacy and safety profiles of antibiotics. Apart from this, they are engaging in collaboration with research institutions, academic organizations, and government bodies to leverage their expertise and address the challenges associated with antibiotic development, such as high costs and regulatory compliances. Moreover, antibiotic companies are actively promoting antibiotic stewardship programs that encourage responsible and appropriate use of antibiotics to avoid overdosage and misusage. Furthermore, companies are increasingly conducting clinical trials and adhering to safety and efficacy standards to obtain regulatory approvals for their antibiotics.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
  • Allergan Plc (AbbVie Inc.)
  • Basilea Pharmaceutica AG
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Melinta Therapeutics
  • Merck & Co. Inc.
  • Nabriva Therapeutics Plc
  • Paratek Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Spero Therapeutics
  • Tetraphase Pharmaceuticals

Recent Developments:

  • In 2021, Sandoz, a Novartis division, successfully completed the acquisition of GlaxoSmithKline’s (GSK) cephalosporin antibiotics business. This acquisition provides them rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets to Sandoz.
  • In January 2020, Merck & Co. Inc. announced that U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for DIFICID® (fidaxomicin) for oral suspension, and a supplemental New Drug Application (sNDA) for DIFICID tablets for the treatment of Clostridioides (formerly Clostridium) difficile-associated diarrhea (CDAD) in children aged six months and older.

Key Questions Answered in This Report

1. How big is the global antibiotics market?
2. What is the expected growth rate of the global antibiotics market during 2024-2032?
3. What are the key factors driving the global antibiotics market?
4. What has been the impact of COVID-19 on the global antibiotics market?
5. What is the breakup of the global antibiotics market based on the action mechanism?
6. What is the breakup of the global antibiotics market based on the drug class?
7. What is the breakup of the global antibiotics market based on the spectrum of activity?
8. What is the breakup of the global antibiotics market based on the route of administration?
9. What is the breakup of the global antibiotics market based on the end user?
10. What are the key regions in the global antibiotics market?
11. Who are the key players/companies in the global antibiotics market?

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Antibiotics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Action Mechanism
6.1 Cell Wall Synthesis Inhibitors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Protein Synthesis Inhibitors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 DNA Synthesis Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 RNA Synthesis Inhibitors
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Mycolic Acid Inhibitors
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 Market Breakup by Drug Class
7.1 Cephalosporin
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Penicillin
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Fluoroquinolone
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Macrolide
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Carbapenem
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Aminoglycoside
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Others
7.7.1 Market Trends
7.7.2 Market Forecast
8 Market Breakup by Spectrum of Activity
8.1 Broad-Spectrum Antibiotics
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Narrow-Spectrum Antibiotics
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by Route of Administration
9.1 Oral
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Parenteral
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Topical
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast
10 Market Breakup by End User
10.1 Hospitals
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Specialty Clinics
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Others
10.3.1 Market Trends
10.3.2 Market Forecast
11 Market Breakup by Region
11.1 North America
11.1.1 United States
11.1.1.1 Market Trends
11.1.1.2 Market Forecast
11.1.2 Canada
11.1.2.1 Market Trends
11.1.2.2 Market Forecast
11.2 Asia-Pacific
11.2.1 China
11.2.1.1 Market Trends
11.2.1.2 Market Forecast
11.2.2 Japan
11.2.2.1 Market Trends
11.2.2.2 Market Forecast
11.2.3 India
11.2.3.1 Market Trends
11.2.3.2 Market Forecast
11.2.4 South Korea
11.2.4.1 Market Trends
11.2.4.2 Market Forecast
11.2.5 Australia
11.2.5.1 Market Trends
11.2.5.2 Market Forecast
11.2.6 Indonesia
11.2.6.1 Market Trends
11.2.6.2 Market Forecast
11.2.7 Others
11.2.7.1 Market Trends
11.2.7.2 Market Forecast
11.3 Europe
11.3.1 Germany
11.3.1.1 Market Trends
11.3.1.2 Market Forecast
11.3.2 France
11.3.2.1 Market Trends
11.3.2.2 Market Forecast
11.3.3 United Kingdom
11.3.3.1 Market Trends
11.3.3.2 Market Forecast
11.3.4 Italy
11.3.4.1 Market Trends
11.3.4.2 Market Forecast
11.3.5 Spain
11.3.5.1 Market Trends
11.3.5.2 Market Forecast
11.3.6 Russia
11.3.6.1 Market Trends
11.3.6.2 Market Forecast
11.3.7 Others
11.3.7.1 Market Trends
11.3.7.2 Market Forecast
11.4 Latin America
11.4.1 Brazil
11.4.1.1 Market Trends
11.4.1.2 Market Forecast
11.4.2 Mexico
11.4.2.1 Market Trends
11.4.2.2 Market Forecast
11.4.3 Others
11.4.3.1 Market Trends
11.4.3.2 Market Forecast
11.5 Middle East and Africa
11.5.1 Market Trends
11.5.2 Market Breakup by Country
11.5.3 Market Forecast
12 SWOT Analysis
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats
13 Value Chain Analysis
14 Porters Five Forces Analysis
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes
15 Price Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 Allergan Plc (AbbVie Inc.)
16.3.1.1 Company Overview
16.3.1.2 Product Portfolio
16.3.1.3 SWOT Analysis
16.3.2 Basilea Pharmaceutica AG
16.3.2.1 Company Overview
16.3.2.2 Product Portfolio
16.3.2.3 Financials
16.3.3 GlaxoSmithKline Plc
16.3.3.1 Company Overview
16.3.3.2 Product Portfolio
16.3.3.3 Financials
16.3.3.4 SWOT Analysis
16.3.4 Johnson & Johnson
16.3.4.1 Company Overview
16.3.4.2 Product Portfolio
16.3.4.3 Financials
16.3.4.4 SWOT Analysis
16.3.5 Melinta Therapeutics
16.3.5.1 Company Overview
16.3.5.2 Product Portfolio
16.3.5.3 Financials
16.3.6 Merck & Co. Inc.
16.3.6.1 Company Overview
16.3.6.2 Product Portfolio
16.3.6.3 Financials
16.3.6.4 SWOT Analysis
16.3.7 Nabriva Therapeutics Plc
16.3.7.1 Company Overview
16.3.7.2 Product Portfolio
16.3.8 Paratek Pharmaceuticals Inc.
16.3.8.1 Company Overview
16.3.8.2 Product Portfolio
16.3.8.3 Financials
16.3.9 Pfizer Inc.
16.3.9.1 Company Overview
16.3.9.2 Product Portfolio
16.3.9.3 Financials
16.3.9.4 SWOT Analysis
16.3.10 Sanofi SA
16.3.10.1 Company Overview
16.3.10.2 Product Portfolio
16.3.10.3 Financials
16.3.10.4 SWOT Analysis
16.3.11 Spero Therapeutics
16.3.11.1 Company Overview
16.3.11.2 Product Portfolio
16.3.11.3 Financials
16.3.12 Tetraphase Pharmaceuticals
16.3.12.1 Company Overview
16.3.12.2 Product Portfolio
List of Figures
Figure 1: Global: Antibiotics Market: Major Drivers and Challenges
Figure 2: Global: Antibiotics Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Antibiotics Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Antibiotics Market: Breakup by Action Mechanism (in %), 2023
Figure 5: Global: Antibiotics Market: Breakup by Drug Class (in %), 2023
Figure 6: Global: Antibiotics Market: Breakup by Spectrum of Activity (in %), 2023
Figure 7: Global: Antibiotics Market: Breakup by Route of Administration (in %), 2023
Figure 8: Global: Antibiotics Market: Breakup by End User (in %), 2023
Figure 9: Global: Antibiotics Market: Breakup by Region (in %), 2023
Figure 10: Global: Antibiotics (Cell Wall Synthesis Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Antibiotics (Cell Wall Synthesis Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Antibiotics (Protein Synthesis Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Antibiotics (Protein Synthesis Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Antibiotics (DNA Synthesis Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Antibiotics (DNA Synthesis Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Antibiotics (RNA Synthesis Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Antibiotics (RNA Synthesis Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Antibiotics (Mycolic Acid Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Antibiotics (Mycolic Acid Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Antibiotics (Other Action Mechanisms) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Antibiotics (Other Action Mechanisms) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Antibiotics (Cephalosporin) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Antibiotics (Cephalosporin) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Antibiotics (Penicillin) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Antibiotics (Penicillin) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Antibiotics (Fluoroquinolone) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Antibiotics (Fluoroquinolone) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Antibiotics (Macrolide) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Antibiotics (Macrolide) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Global: Antibiotics (Carbapenem) Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Global: Antibiotics (Carbapenem) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Global: Antibiotics (Aminoglycoside) Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Global: Antibiotics (Aminoglycoside) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Global: Antibiotics (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Global: Antibiotics (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Global: Antibiotics (Broad-Spectrum Antibiotics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Global: Antibiotics (Broad-Spectrum Antibiotics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Global: Antibiotics (Narrow-Spectrum Antibiotics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Global: Antibiotics (Narrow-Spectrum Antibiotics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: Global: Antibiotics (Oral) Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: Global: Antibiotics (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Global: Antibiotics (Parenteral) Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Global: Antibiotics (Parenteral) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Global: Antibiotics (Topical) Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Global: Antibiotics (Topical) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Global: Antibiotics (Other Routes of Administration) Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Global: Antibiotics (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Global: Antibiotics (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Global: Antibiotics (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Global: Antibiotics (Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Global: Antibiotics (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Global: Antibiotics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Global: Antibiotics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: North America: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: North America: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: United States: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: United States: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Canada: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Canada: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Asia-Pacific: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Asia-Pacific: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: China: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: China: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Japan: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Japan: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: India: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: India: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: South Korea: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: South Korea: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Australia: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Australia: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Indonesia: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: Indonesia: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: Others: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: Others: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 76: Europe: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 77: Europe: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 78: Germany: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 79: Germany: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 80: France: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 81: France: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 82: United Kingdom: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 83: United Kingdom: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 84: Italy: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 85: Italy: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 86: Spain: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 87: Spain: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 88: Russia: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 89: Russia: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 90: Others: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 91: Others: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 92: Latin America: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 93: Latin America: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 94: Brazil: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 95: Brazil: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 96: Mexico: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 97: Mexico: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 98: Others: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 99: Others: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 100: Middle East and Africa: Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
Figure 101: Middle East and Africa: Antibiotics Market: Breakup by Country (in %), 2023
Figure 102: Middle East and Africa: Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 103: Global: Antibiotics Industry: SWOT Analysis
Figure 104: Global: Antibiotics Industry: Value Chain Analysis
Figure 105: Global: Antibiotics Industry: Porter's Five Forces Analysis
List of Tables
Table 1: Global: Antibiotics Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Antibiotics Market Forecast: Breakup by Action Mechanism (in Million US$), 2024-2032
Table 3: Global: Antibiotics Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
Table 4: Global: Antibiotics Market Forecast: Breakup by Spectrum of Activity (in Million US$), 2024-2032
Table 5: Global: Antibiotics Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
Table 6: Global: Antibiotics Market Forecast: Breakup by End User (in Million US$), 2024-2032
Table 7: Global: Antibiotics Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 8: Global: Antibiotics Market: Competitive Structure
Table 9: Global: Antibiotics Market: Key Players

Companies Mentioned

  • Allergan Plc (AbbVie Inc.)
  • Basilea Pharmaceutica AG
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Melinta Therapeutics
  • Merck & Co. Inc.
  • Nabriva Therapeutics Plc
  • Paratek Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Spero Therapeutics
  • Tetraphase Pharmaceuticals etc.

Methodology

Loading
LOADING...

Table Information